TY - JOUR
T1 - Ischemic Heart Disease
T2 - Special Considerations in Cardio-Oncology
AU - Giza, Dana Elena
AU - Boccalandro, Fernando
AU - Lopez-Mattei, Juan
AU - Iliescu, Gloria
AU - Karimzad, Kaveh
AU - Kim, Peter
AU - Iliescu, Cezar
N1 - Publisher Copyright:
© 2017, Springer Science+Business Media New York.
PY - 2017/5/1
Y1 - 2017/5/1
N2 - The interplay and balance between the competing morbidity and mortality of cardiovascular diseases and cancer have a significant impact on both short- and long-term health outcomes of patients who survived cancer or are being treated for cancer. Ischemic heart disease in patients with cancer or caused by cancer therapy is a clinical problem of emerging importance. Prompt recognition and optimum management of ischemic heart disease mean that patients with cancer can successfully receive therapies to treat their malignancy and reduce morbidity and mortality due to cardiovascular disease. In this sense, the presence of cancer and cancer-related comorbidities (e.g., thrombocytopenia, propensity to bleed, thrombotic status) substantially complicates the management of cardiovascular diseases in cancer patients. In this review, we will summarize the current state of knowledge on the management strategies for ischemic disease in patients with cancer, focusing on the challenges encountered when addressing these complexities.
AB - The interplay and balance between the competing morbidity and mortality of cardiovascular diseases and cancer have a significant impact on both short- and long-term health outcomes of patients who survived cancer or are being treated for cancer. Ischemic heart disease in patients with cancer or caused by cancer therapy is a clinical problem of emerging importance. Prompt recognition and optimum management of ischemic heart disease mean that patients with cancer can successfully receive therapies to treat their malignancy and reduce morbidity and mortality due to cardiovascular disease. In this sense, the presence of cancer and cancer-related comorbidities (e.g., thrombocytopenia, propensity to bleed, thrombotic status) substantially complicates the management of cardiovascular diseases in cancer patients. In this review, we will summarize the current state of knowledge on the management strategies for ischemic disease in patients with cancer, focusing on the challenges encountered when addressing these complexities.
KW - Antiplatelet therapy
KW - Cancer
KW - Cardiotoxicity
KW - Ischemic heart disease
KW - PCI
KW - Radiation
UR - http://www.scopus.com/inward/record.url?scp=85017635751&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85017635751&partnerID=8YFLogxK
U2 - 10.1007/s11936-017-0535-5
DO - 10.1007/s11936-017-0535-5
M3 - Review article
C2 - 28425056
AN - SCOPUS:85017635751
SN - 1092-8464
VL - 19
JO - Current Treatment Options in Cardiovascular Medicine
JF - Current Treatment Options in Cardiovascular Medicine
IS - 5
M1 - 37
ER -